glp-1 medication program If you're covered by the State Health Benefit Plan (SHBP) and take a weight-loss (like Wegovy or Zepbound), a change is coming. Starting February 1, 2026, SHBP will require these What to Make of the

Localized injection site reactions including mild itching may occur, but generalized pruritus appears relatively uncommon based on clinical trial data

Mayer, A

These tests are called nerve conduction studies and electromyography (EMG)

Understanding injection frequency is essential for treatment adherence and outcomes

Study period 1/1/2021 to 10/1/2024 with follow-up possible through 7/1/2025 Study population: inclusion Patients with: PCOS (encounter or billing diagnosis with ICD-10-CM code E28.2) before exposure or within two years of drug trial start Evaluated sex of female or ambiguous Aged 18 to 50 at drug trial start No overlap in metformin and GLP-1 use At least one measurement within one year prior to trial start At least one measurement 9 to 15 months after trial start At least 70% of days covered by their exposure medication dispense Study population: exclusion Patients with: Evidence of pregnancy during baseline or outcome measurements Definitive pregnancy start date: Between 12 months before the first reading through the follow-up reading Definitive pregnancy end date, delivery, or if its ambiguous what point in the pregnancy the patient would be at (e.g